The LAMEA Cataract Surgery Devices Market would witness market growth of 5% CAGR during the forecast period (2017 – 2023).
Cataract surgery devices are majorly used in surgical procedures that are focused on treating cataract, an eye disorder which clouds the lens, and as a result, leads to defects in vision. Cataract is among the most common diseases which leads to blindness, reducing vision ability. Cataract is known to develop slowly and affects either one or both the eyes. Cataract does not directly interfere with the eyesight in its early stages; nevertheless, it interferes with vision and leads blindness over the years.
Increase in incidences of diseases such as diabetes, obesity, hypertension and growth in geriatric population contributes to the growth of the market. Lack of skilled professionals is a major cause that would limit the market growth during the forecast period. Considering the case, the governments and non-profit organizations around the world are introducing programs to reduce the burden of cataract-related diseases, which would offer tremendous opportunities for key market players.
Based on Type, the market is segmented into Equipment and Consumables. Based on product, the market is segmented into Intraocular Lens (IOL), Ophthalmic Viscoelastic Device (OVD), and Phacoemulsification Equipment. The end User covered under the report are Hospitals, Ophthalmology Clinics, and Ambulatory Surgery Centers. The report also cover country wide segmentation. The countries included in the report are Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the LAMEA Cataract Surgery Devices Market. Key companies profiled in the report include Novartis Ag, Abbott Laboratories, Carl Zeiss Meditec Ag, Essilor International S.A, Johnson & Johnson, Haag-Streit Holding Ag, Topcon Corporation, Nidek Co., Ltd, Valeant Pharmaceuticals International, Inc., and Ziemer Ophthalmic Systems Ag.